Les perspectives thérapeutiques des cytokines en matière d'allergie respiratoire [Therapeutic perspectives of cytokines in respiratory allergy conditions]

Détails

ID Serval
serval:BIB_EE902FA5EBC7
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Les perspectives thérapeutiques des cytokines en matière d'allergie respiratoire [Therapeutic perspectives of cytokines in respiratory allergy conditions]
Périodique
Allergie et Immunologie
Auteur⸱e⸱s
Nicod L.P.
ISSN
0397-9148[print], 0397-9148[linking]
Statut éditorial
Publié
Date de publication
1992
Volume
24
Numéro
6
Pages
197-198
Langue
français
Notes
Publication types: English Abstract ; Journal Article ; Review
Résumé
Among the cytokines playing a role in asthma, IL-1 and TNF alpha or beta are important agents to be considered. IL-1 TNF alpha are produced by antigen-presenting cells. TNF alpha and beta are released by activated lymphocytes. Recently a natural inhibitor of IL-1 produced by monocytes or macrophages in the form of a 22-25 kD protein, which binds competitively to IL-1 receptors has been cloned and sequenced. This inhibitor is called the IL-1 receptors antagonist. Two types of TNF soluble receptors (55 and 75 kD) can be liberated from the surface of macrophages and neutrophils. These soluble receptors block both TNF alpha and beta activity. The respective roles of these cytokine inhibitors in the physiopathology of asthma need to be further defined, but new therapeutic perspectives are opening.
Mots-clé
Asthma/physiopathology, Asthma/therapy, Humans, Immunologic Factors/therapeutic use, Lymphokines/therapeutic use, Models, Biological, Receptors, Cell Surface/antagonists & inhibitors, Receptors, Cell Surface/physiology, Receptors, Immunologic/antagonists & inhibitors, Receptors, Interleukin-1, Receptors, Tumor Necrosis Factor, Respiratory Hypersensitivity/physiopathology, Respiratory Hypersensitivity/therapy, Tumor Necrosis Factor-alpha/antagonists & inhibitors, Tumor Necrosis Factor-alpha/physiology
Pubmed
Création de la notice
19/02/2010 20:40
Dernière modification de la notice
20/08/2019 17:16
Données d'usage